SEC Form 4 · accession 0001628280-26-062490
Arcutis Biotherapeutics, Inc. · ARQT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Howard G. Welgus
Director
Period of report
Sep 15, 2026
Accepted (ET)
Sep 17, 2026 · 4:06 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001787306
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 15, 2026 | M | 822 | $6.5223 | A | 37,297 | D | |
| Common Stock | Sep 15, 2026 | M | 1,019 | $7.51 | A | 38,316 | D | |
| Common Stock | Sep 15, 2026 | M | 2,255 | $8.63 | A | 40,571 | D | |
| Common Stock | Sep 15, 2026 | S | 4,730 | $24.18 | D | 35,841 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $6.5223 | Sep 15, 2026 | M | 822 | D | — | Nov 20, 2029 | Common Stock | 822 | 6,574 | D |
| Stock Option (right to buy)F2 | $7.51 | Sep 15, 2026 | M | 1,019 | D | — | May 31, 2033 | Common Stock | 1,019 | 8,144 | D |
| Stock Option (right to buy)F2 | $8.63 | Sep 15, 2026 | M | 2,255 | D | — | Jun 14, 2034 | Common Stock | 2,255 | 18,032 | D |
Explanation of responses
- F1The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027.
- F2The option is fully vested.